新发ETF将批量上市。7月29日，6只ETF集中发布上市交易公告书，7月30日以来，又有3只ETF发布上 市交易公告书。从这批ETF上市时间看：南方中证机器人ETF、永赢中证港股通央企红利ETF、华安国 证航天航空行业ETF、博时恒生港股通创新药精选ETF、广发上证科创板100ETF、国泰上证科创板创新 药ETF将集中在8月1日上市。易方达国证通用航空产业ETF、华夏创业板软件ETF将在8月4日上市，华 夏中证500自由现金流ETF将在8月5日上市。 从上述ETF披露的最新股票仓位看，截至7月28日，华夏创业板软件ETF的权益投资占基金总资产比例 为19.92%，易方达国证通用航空产业ETF的权益投资占基金总资产比例为10.01%。此外，截至7月25 日，广发上证科创板100ETF、国泰上证科创板创新药ETF等的权益投资占基金总资产比例均低于30%。 ETF阵营有望继续大幅扩容。Choice数据显示，截至7月31日，当前共有超10只ETF正在或即将发行。从 ETF投向看，涵盖中证500、创业板50、中证A500等宽基指数，也包括科创板人工智能、港股科技、通 用航空等细分行业主题指数。此外，当前还有超10只ET ...

华夏中证500自由现金流ETF今日发布上市公告书，基金将于2025年8月5日上市，上市交易份额为3.87 亿份，该基金成立日为2025年7月23日，截至2025年7月29日，基金投资组合中，银行存款和结算备付金 合计占基金总资产的比例为64.45%，股票投资占基金总资产的比例为35.55%，目前基金仍处于建仓 期。 证券时报·数据宝统计，7月以来共有31只股票型ETF公告上市，平均仓位仅为19.32%，仓位最高的是汇 添富国证通用航空产业ETF，仓位为42.30%，仓位居前的还有鹏华科创板芯片ETF、华夏中证500自由 现金流ETF、华夏上证智选科创板价值50策略ETF，仓位分别为39.29%、35.55%、34.07%，仓位较低的 为华宝恒生港股通创新药精选ETF、博时恒生港股通创新药精选ETF、天弘中证A100ETF，仓位分别为 0.00%、0.00%。 一般来说，ETF上市都要满足基金合同规定的仓位要求，发布上市公告书，距离正式上市时间会差几个 交易日，其间如果仓位较低，会在上市前完成建仓。 7月以来公告上市的ETF中，按上市交易份额统计，平均募集4.61亿份，规模居前的有广发恒生港股通 科技主题ETF ...

Group 1 - Six stock ETFs have released listing announcements, with varying stock positions: 博时恒生港股通创新药精选ETF at 0.00%, 港股通央企红利ETF at 19.79%, 广发上证科创板100ETF at 27.75%, 国泰上证科创板创新药ETF at 24.20%, 华安国证航天航空行业ETF at 19.93%, and 南方中证机器人ETF at 12.58% [1] - Since July, a total of 28 stock ETFs have announced listings, with an average position of 19.04%. The highest position is held by 汇添富国证通用航空产业ETF at 42.30% [1][2] - ETF listings must meet the position requirements specified in the fund contract, and if the position is low, it will be completed before the official listing [1] Group 2 - The average number of shares raised for the newly announced ETFs since July is 4.67 million, with the largest being 广发恒生港股通科技主题ETF at 13.41 million shares [2] - Institutional investors hold an average of 12.15% of the shares, with the highest being 汇添富国证港股通消费主题ETF at 85.50% [2] - The newly established stock ETFs have varying positions during the construction period, with 南方中证机器人ETF at 12.58%, 博时恒生港股通创新药精选ETF at 0.00%, and 广发上证科创板100ETF at 27.75% [3]

Institutional Movements - Long-term funds are continuously increasing their investments in the innovative drug sector amid recent market adjustments, indicating a long-term value in this sector, although a focus on quality companies is necessary due to previous strong price increases [1] Long-term Funds Entering via ETFs - Several newly launched innovative drug-themed ETFs have seen significant purchases from long-term funds this year, with Barclays Bank being a major holder of multiple ETFs, holding 20 million yuan in one and 85 million yuan in another [2] - Corporate pension plans have also heavily invested in innovative drug ETFs, with several plans holding over 40 million yuan each [2] - As of July 3, the Huatai-PineBridge Hang Seng Innovative Drug ETF has increased by over 60% since its launch, while the ICBC Credit Suisse National Index Hong Kong Innovative Drug ETF has risen nearly 30% [2] Fund Flows - The innovative drug-themed ETFs have attracted substantial net subscriptions, totaling nearly 9 billion yuan since June, with specific ETFs like the Huatai-PineBridge and GF Hong Kong Innovative Drug ETFs seeing net subscriptions of 4.44 billion yuan and 2.305 billion yuan, respectively [3] New Fund Launches - Public funds are increasing their focus on innovative drug-themed funds, with several new funds currently being issued, including the Xinyuan CSI Hong Kong Innovative Drug Index Fund and others set to launch soon [4] Long-term Outlook for the Innovative Drug Industry - The innovative drug sector in China is expected to continue its long-term positive trend, with significant overseas collaborations and clinical advancements being recognized by multinational pharmaceutical companies [5] - The recent rise in the innovative drug sector is attributed to a decade of accumulated competitive advantages rather than short-term market fluctuations, suggesting ongoing investment opportunities in quality innovative drug companies [5] - The industry is likely to experience linear development, while market performance may be more volatile, necessitating a focus on fundamental research and selective investment strategies [5]